专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1991003271A1 APPARATUS FOR ADMINISTERING MEDICAMENTS TO MUCOSAL TISSUE 审中-公开
标题翻译：用于管理粘膜组织的药物的装置
公开(公告)号：WO1991003271A1
公开(公告)日：1991-03-21
申请号：PCT/US1990004368
申请日：1990-08-03
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , STANLEY, Theodore, H.
IPC分类号： A61M37/00
CPC分类号： A61K9/703 , A23G3/368 , A61K9/0056 , A61K9/7084 , A61K31/465
摘要： Apparatus and method for the dose-to-effect transmucosal administration of medicaments are disclosed. The invention relates to a disk-shaped control member (22) defining a plurality of openings (24) on one semicircle of the control member (22), positioned adjacent the medicament chamber base (14). An adhesive material (26) located on the control member (22) rotates relative to housing (12) to increase or decrease the effective area of medicament chamber opening (18).
摘要翻译：公开了用于剂量效应的经粘膜给药的装置和方法。本发明涉及在控制构件（22）的一个半圆上限定多个开口（24）的盘形控制构件（22），其位于邻近药剂室底座（14）处。位于控制构件（22）上的粘合剂材料（26）相对于壳体（12）旋转以增加或减少药物室开口（18）的有效面积。

2. 发明申请

WO1991003233A1 METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS 审中-公开
标题翻译：非毒性药物对药物的效果管理的方法和组合物
公开(公告)号：WO1991003233A1
公开(公告)日：1991-03-21
申请号：PCT/US1989003801
申请日：1989-09-05
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , STANLEY, Theodore, H. , HAGUE, Brian
IPC分类号： A61K09/20
CPC分类号： A61K9/0056
摘要： The present invention is directed to methods and compositions for noninvasively administering lipophilic drugs in a dose-to-effect manner to produce antimigraine, oxytoxic, antiemetic, hypoglycemic, anti-Parkinsonian, antidiuretic, antifungal, antisecretory, or bronchodilator activity. A patient is put at ease when given the lollipop, and the lipophilic drug rapidly enters the patient's bloodstream as the lollipop is sucked. When treating the patient, the physician can observe the patient's condition and terminate the use of the lollipop when it has had a desired effect on the patient. The drug-containing lollipop can be self-administered by the patient in response to subjective symptoms and to the patient's susceptibility to the lipophilic drug.
摘要翻译：本发明涉及以剂量效应方式非侵入性地施用亲脂性药物以产生抗偏头痛，含氧毒性，止吐药，降血糖，抗帕金森病，抗利尿，抗真菌，抗分泌或支气管扩张剂活性的方法和组合物。当给予棒棒糖时，患者放心，并且当吸食棒棒糖时，亲脂性药物迅速进入病人的血液流中。当治疗患者时，医生可以观察患者的状况，并且当对患者具有期望的效果时终止棒棒糖的使用。药物的棒棒糖可以由患者自主施用以响应主观症状和患者对亲脂性药物的易感性。

3. 发明申请

WO1991003237A1 COMPOSITIONS AND METHODS OF MANUFACTURE OF ORAL DISSOLVABLE MEDICAMENTS 审中-公开
标题翻译：口腔不溶性药物的制备及其制备方法
公开(公告)号：WO1991003237A1
公开(公告)日：1991-03-21
申请号：PCT/US1990004384
申请日：1990-08-03
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , STANLEY, Theodore, H. , HAGUE, Brian
IPC分类号： A61K09/68
CPC分类号： A23G3/368 , A23G3/54 , A23G3/563 , A24B15/16 , A24F47/002 , A61J3/00 , A61J7/003 , A61K9/0056 , A61K31/465
摘要： Dosage form and method of manufacture for producing a medicament capable of absorption through mucosal tissues. The drug (24) is to be incorporated into a dissolvable matrix (22). An appliance or holder (26) is attached to the dissolvable matrix (22) and mounted or sealed against button (28).
摘要翻译：用于制备能够通过粘膜组织吸收的药物的剂型和制造方法。将药物（24）并入可溶性基质（22）中。器具或保持器（26）附接到可溶解基质（22）并安装或密封抵靠按钮（28）。

4. 发明申请

WO1991003234A1 DRUG CONTAINING MATRIX 审中-公开
标题翻译：含有药物基质
公开(公告)号：WO1991003234A1
公开(公告)日：1991-03-21
申请号：PCT/US1989003802
申请日：1989-09-05
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , STANLEY, Theodore, H. , HAGUE, Brian
IPC分类号： A61K09/20
CPC分类号： A23G3/368 , A61K9/0056 , A61K31/465 , Y10S426/801 , Y10S514/948
摘要： The present invention is directed to methods and compositions for noninvasively administering drugs in a dose-to-effect manner to produce a cardiovascular or renal vascular activity. A cardiovascular or renal vascular drug, which is capable of absorption through mucosal tissues of the mouth, pharynx, and esophagus is incorporated into a matrix which is in the form of a lollipop. A patient is put at ease when given the lollipop, and the drug rapidly enters the patient's bloodstream as the lollipop is sucked. When treating the patient, the physician can observe the patient's condition and remove the lollipop when it has had a desired effect on the patient. A lollipop into which a cardiovascular or renal vascular drug has been dispersed is particularly useful for achieving rapid vasodilating, calcium channel blocking, beta-blocking, seritonin receptor blocking, angina blocking, anti-hypertensive, and cardiac stimulating effects and for controlling urine output.
摘要翻译：镇静剂，止痛剂或麻醉剂。包括：有效剂量的有效剂量（I），能够通过粘膜组织吸收，均匀分散在溶解在口腔释放（I）中的可溶性基质（II）中，以及固定在药物接触物上的保持剂。基体构造成当获得期望的条件时允许插入和从口中移除。 compsn。尤其是以棒棒糖的形式。

5. 发明申请

WO1991003236A1 TRANSMUCOSAL DOSAGE FORM 审中-公开
标题翻译：转运剂量形式
公开(公告)号：WO1991003236A1
公开(公告)日：1991-03-21
申请号：PCT/US1990004369
申请日：1990-08-03
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , STANLEY, Theodore, H. , HAGUE, Brian
IPC分类号： A61K09/68
CPC分类号： A23G3/368 , A23G3/54 , A23G3/563 , A61J3/00 , A61J7/00 , A61J7/003 , A61K9/0056 , A61K31/465
摘要： Compositions and methods of manufacture for producing a medicament composition capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus. The present invention relates to such compositions and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufacturing techniques that enable therapeutic agents (30) to be incorporated into nondissolvable drug containment matrixes (34) which are capable of releasing the drug within a patient's mouth. An appliance or holder (36) is preferably attached to the drug containment matrix (34). Employing the present invention the drug (30) may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the negative aspects of both of these methods. The nondissolvable drug containment matrix (34) may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The matrix composition (34) may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug (30) through the mucosal tissues.
摘要翻译：用于生产能够通过口，咽和食道的粘膜组织吸收的药物组合物的组合物和制造方法。本发明涉及这样的组合物和方法，其可用于以剂量 - 效应方式施用亲脂性和非嗜好性药物，使得施用足够的药物以精确地产生所需效果。本发明还涉及使治疗剂（30）能够并入不可溶解的药物容纳基质（34）中的制造技术，其能够在患者口腔内释放药物。器具或保持器（36）优选地附接到药物容纳基质（34）。使用本发明，药物（30）可以几乎与通过注射一样快地引入患者的血液中，并且比使用口服给药途径快得多，同时避免了这两种方法的不利方面。不可溶解的药物抑制基质（34）可以包括渗透促进剂以增加口腔粘膜组织的药物吸收。基质组合物（34）还可以包括pH缓冲剂，以改变游离pH，从而增加药物（30）通过粘膜组织的吸收。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式